


PHARMACEUTICAL 2021

G1 Therapeutics Inc. Rank 216 of 409







PHARMACEUTICAL 2021

G1 Therapeutics Inc. Rank 216 of 409



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 41% points. The greatest weakness of G1 Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is -149%, being 206% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	216,392
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,443
Liabilities, Non-Current	7,865
Other Assets	9,678
Other Compr. Net Income	0
Other Expenses	1,410
Other Liabilities	19,893
Other Net Income	-1,368
Property and Equipment	2,482
Research and Development	73,271
Revenues	45,285
Selling, General and Administrative Expense	68,490

Output Variable	Value in 1000 USD
Assets	228,552
Liabilities	51,201
Expenses	143,171
Stockholders Equity	177,351
Net Income	-99,254
Comprehensive Net Income	-99,254
Economic Capital Ratio	-149%